

EBMT Transplantation and Cellular Therapy in Myeloid Malignancies Meeting

Paris, France | 21-22 January 2027



Acute
Leukaemia
ALWP



Chronic
Malignancies
CMWP

Thursday, 21 January 2027

09:00 – 13:00

Scientific Business Meetings

14:00 – 16:00

Session I: Novel insights on allo-HCT indications and management

Chairs: *Giorgia Battipaglia (IT) & Joanna Drozd-Sokołowska (PL)*

14:00 – 14:15

Welcome and Introduction

14:15 – 14:35

Allo-HCT Recommendation in Non-Classical MPN and MDS/MPN

14:35 – 14:55

Defining Remission and Relapse in MDS/MPN Overlaps

14:55 – 15:15

Update on Allo-HCT Indications in AML

15:15 – 15:35

Update on Allo-HCT for ALL in CR1

15:35 – 15:45

Oral Presentation: An unusual case of multiply relapsed acute promyelocytic leukaemia

15:45 – 15:55

Oral Presentation: Novel Insights into Allo-HCT Indications and Long-Term Management in an Older Patient with High-Risk Systemic Mastocytosis Associated with CMML and Severe Hepatic Infiltration

15:55 – 16:00

Discussion

Marie Robin (FR)

Eolia Brissot (FR)

Nicola Polverelli (IT)

Donal McLornan (UK)

Jordi Esteve (ES)

Sebastian Giebel (PL)

Carlangela Causa (IT)

Covadonga Lomo Martínez (ES)

16:00 – 16:30

Coffee Break

16:30 – 17:15

Industry Symposium Slot

17:15 – 18:45

Session II: Session II: Allo-HCT in high-risk AML or MDS

Chairs: *Kavita Raj (UK) & Fabio Ciceri (IT) & Angeliki Georgopoulou (GR)*

17:15 – 17:35

Role of Allo-HCT in High-Risk AML

17:35 – 17:55

Upfront versus Cytoreduction before Transplant in MDS

17:55 – 18:15

Maintenance Post Allo in AML

18:15 – 18:25

Oral Presentation: Allogeneic stem cell transplantation in relapsed/refractory acute myeloid leukaemia with active disease: the role of prophylactic post-transplant strategies to enhance Graft versus Leukaemia effect

18:25 – 18:35

Oral Presentation: Acquired ETV6::ABL1 Fusion during Clonal Evolution of NPM1-Mutated FLT3-ITD Acute Myeloid Leukaemia

18:35 – 18:45

Discussion

Annalisa Ruggeri (IT)

Marie Robin (FR)

Jaime Sanz (ES)

Federica Frenza (IT)

Manuel Alegre Antelo (ES)

For further information, please get in contact with education.events@ebmt.org

EBMT Transplantation and Cellular Therapy in Myeloid Malignancies Meeting

Paris, France | 21-22 January 2027



Acute
Leukaemia
ALWP



Chronic
Malignancies
CMWP

Friday, 22 January 2027

09:00 – 10:30 Session III: CAR-T Cell Therapy for ALL and AML/MDS: Where Do We Stand?

Chairs: Arnon Nagler (IL) & Guillermo Orti (ES)

09:00 – 09:20 Up to Date on CAR-T Therapy for AML and High-Risk MDS

09:20 – 09:40 Calreticulin-Targeted CAR T-cell Therapy in MPN

09:40 – 10:00 Update CAR-T in ALL

10:00 – 10:10 *Oral Presentation:* Paraneoplastic Spondyloarthritis-like Syndrome Tracking Leukemic Burden in Early-Relapsed, Refractory Acute Myeloid Leukaemia

10:10 – 10:30 Discussion

Joanna Drozd-Sokołowska (PL)

Alex Rampotas (UK)

Eolia Brissot (FR)

Abdul Walli Cana (PH)

10:30 – 11:30 Keynote Lecture

Chair: Marie Robin (FR)

10:30 – 11:15 Innovative therapies in myelofibrosis

11:15 – 11:30 Q&A

Jean-Jacques Kiladjian (FR)

11:30 – 12:00 Coffee Break

12:00 – 12:45 Industry Symposium Slot

12:45 – 14:15 Session IV: Post Allo-HCT Management in BCR::ABL1 mutated leukaemias

Chairs: Gesine Bug (DE) & Yves Chalandon (CH)

12:45 – 13:05 EBMT-Lead Expert Recommendation on CML Management Post Allo-HCT

13:05 – 13:25 Optimizing Management of Ph+ ALL after Transplant and CAR-T Cells

13:25 – 13:45 How to Assess Quality of Life After Transplantation

13:45 – 13:55 *Oral Presentation:* Isolated central nervous system blast crisis in chronic Myeloid leukaemia: diagnosis despite a normal marrow and salvage with allogeneic transplantation

13:55 – 14:15 Discussion

Hugues de Lavallade (UK)

Gesine Bug (DE)

Chiara Giacon (IT)

To be announced

14:15 – 14:45 Coffee Break

14:45 – 16:45 Session V: Controversies

Chairs: Iman Abou Dalle (LB) & Christoph Scheid (DE)

14:45 – 15:35 Is It Time for PTCy to Replace ATG as the Standard GVHD Prophylaxis in Myeloid Malignancies?

14:45 – 15:05 Yes

15:05 – 15:25 No

15:25 – 15:35 Q&A

15:35 – 16:30 Second Transplantation or DLI in Patients with MDS or AML Relapsing after Transplantation?

15:35 – 15:45 *Oral Presentation:* Isolated CNS relapse of AML shortly after Haploidentical

Allogeneic HSCT in Systemic Mastocytosis with Associated Myeloid Neoplasm

15:45 – 16:05 Second allo

16:05 – 16:25 DLI

16:25 – 16:35 Q&A

16:35 – 16:45 Take Home Messages & Closing Remarks

Patricia Chiusolo (IT)

Giorgia Battipaglia (IT)

All

Ana Mellado (ES)

Giuliano Filippini (DE)

Christoph Schmid (DE)

All

Marie Robin (FR)

Eolia Brissot (FR)

For further information, please get in contact with education.events@ebmt.org